<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DOXAZOSIN MESYLATE</span><br/>(dox-a'zo-sin)<br/><span class="topboxtradename">Cardura<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">alpha-adrenergic antagonist (sympatholytic, adrenergic blocking agent) </span><br/><b>Prototype: </b>Prazosin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg, 2 mg, 4 mg, 8 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>By selective competitive inhibition of alpha<sub>1</sub>-adrenoreceptors, it produces vasodilation in both resistance (arterioles) and capacitance (veins) vessels with the result
         that both peripheral vascular resistance and blood pressure are reduced.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Lowers blood pressure in supine or standing individuals with most pronounced effect on diastolic pressure.</p>
<h1><a name="uses">Uses</a></h1>
<p>Mild to moderate hypertension, benign prostatic hypertrophy.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>CHF.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to doxazosin, prazosin, and terazosin; hypotension, syncope. Safe use during pregnancy (category B) or in
         children is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic impairment or disease; renal disease, impairment, or failure; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 1 mg h.s. and titrate up to maximum of 16 mg/d in 12 divided doses<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 0.5 mg h.s.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give initial dose at bedtime to minimize problems with postural hypotension and syncope.</li>
<li>Individualize maintenance dose according to the standing BP response.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span>
<span class="speceff-common">Orthostatic hypotension,</span> edema. <span class="typehead">CNS:</span> Vertigo, <span class="speceff-common">headache,</span> dizziness, somnolence, fatigue, nervousness, anxiety. <span class="typehead"> GI:</span>  Nausea, abdominal pain. <span class="typehead"> Hematologic:</span>  Leukopenia. <span class="typehead">Skin:</span> Pruritus, eczema. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Sildenafil, vardenafil,</b> and <b>tadalafil</b> may enhance hypotensive effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; 6269% of dose reaches systemic circulation. <span class="typehead">Peak:</span> 26 h. <span class="typehead">Duration:</span> Up to 24 h. <span class="typehead">Distribution:</span> Highly protein bound (9899%). <span class="typehead">Metabolism:</span> Approximately 35% of dose is metabolized in liver. <span class="typehead">Elimination:</span> 9% excreted in urine, 63% in feces. <span class="typehead">Half-Life:</span> 912 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP with patient lying down and standing; doses above 4 mg increase the risk of postural hypotension.</li>
<li>Monitor BP 26 h after initial dose or any dose increase. This is when postural hypotension is most likely to occur.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in other potentially hazardous activities for 1224 h after the first dose or an increase in dosage
            or when medication is restarted after an interruption in dosage.
         </li>
<li>Use caution when rising from a sitting or supine position in order to avoid orthostatic hypotension and syncope; make position
            and directional changes slowly and in stages.
         </li>
<li>Report to the physician episodes of dizziness or palpitations. These will require a dosage adjustment.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>